Firefly Neuroscience has significantly expanded its commercial reach and EEG scan volumes, showcasing a more than 20-fold increase. This growth positions the company favorably to further explore AI-driven biomarker discoveries that may enhance treatment options in neuroscience.
U.S. stocks dipped; Nasdaq fell over 100 points. AIFF shares surged 141% after announcing new research advances. U.S. producer prices increased 0.2% in December, lower than expected.
